Fenretinide lipid matrix - BioMolecular Products/Lym-Drug Products

Drug Profile

Fenretinide lipid matrix - BioMolecular Products/Lym-Drug Products

Alternative Names: 4-HPR/LXS; Fenretinide LYM-X-SORB; HPR/LXS; LXS/4-HPR

Latest Information Update: 28 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biomolecular Products; Lym-Drug Products LLC
  • Developer Academic Medical Center; Childrens Hospital Los Angeles; National Cancer Institute (USA)
  • Class Antineoplastics; Chemopreventatives; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Insulin resistance
  • No development reported Lymphoma; Neuroblastoma; Solid tumours

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Lymphoma in USA (PO, Controlled release)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Neuroblastoma(Combination therapy, Recurrent) in USA (PO, Controlled release)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Neuroblastoma(Recurrent) in USA (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top